ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
EDNRA Forms a Positive Feedback Loop with the Hippo/YAP Axis to Drive Triple-Negative Breast Cancer Progression.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sustained Hippo/Yes-associated protein (YAP) activation drives triple-negative breast cancer (TNBC), but druggable upstream regulators remain unclear. We investigated G protein-coupled receptors (GPCRs) as membrane inputs for YAP activation. TCGA-based Hippo/YAP signature analysis, marketed-drug GPCR annotation, and siRNA screening using connective tissue growth factor (CTGF) identified endothelin receptor type A (EDNRA). EDNRA function was tested by knockdown, overexpression, endothelin-1 (ET-1) stimulation, and atrasentan blockade in TNBC cells and xenografts. YAP regulation was examined by immunoblotting, RT-qPCR, TEAD reporter assays, subcellular localization, docking, co-immunoprecipitation, mutagenesis, ChIP-qPCR, and CRISPRi. EDNRA correlated with Hippo/YAP signatures, adverse clinical features, and poor outcome. EDNRA depletion or atrasentan suppressed proliferation, migration, stem-like populations, and xenograft growth, whereas EDNRA overexpression or ET-1 had opposite effects. Mechanistically, EDNRA reduced YAP Ser127 phosphorylation, promoted nuclear YAP accumulation, and enhanced TEAD transcription through Gαq/11-Rho/ROCK-LATS signaling. Mutating predicted EDNRA-Gαq/11 interface residues impaired YAP activation and tumor-promoting activity. Reciprocally, YAP/TEAD4 enhanced EDNRA transcription through an enhancer-associated region. Atrasentan also sensitized TNBC cells to paclitaxel and produced positive zero interaction potency (ZIP) synergy scores. EDNRA establishes a druggable positive feedback loop with Hippo/YAP signaling and represents a potential therapeutic vulnerability in YAP-driven TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.